PMV Pharma
Cranbury, US · Founded 2013 · 6 known investors
Find your way into PMV Pharma
216 people in our graph share verified history with the PMV Pharma team — schools, employers, funds. One of them is your warm intro.
Sam Blackmanunlockedknows David H. Mack, Ph.D. · together at University of Chicago (overlapped)
×9knows the team · via Stanford University School of Medicine
×2knows the team · via University of Chicago
PMV Pharma develops precision oncology therapies that target and structurally correct mutated p53 proteins to restore their tumor-suppressing function. The company focuses on treating cancers driven by p53 mutations.
Founders & leadership
PMV Pharma was founded in 2013 by David H. Mack, Ph.D..
DH
David H. Mack, Ph.D.inFounder · President & CEOformerDavid Mack holds a Ph.D. in molecular genetics from the University of Chicago and a B.A. in molecular biology from UC Berkeley. He previously served as a general partner at Alta Partners, co-founded Eos Biotechnology, and held leadership roles at Affymetrix and Cetus, with scientific publications in top-tier journals and multiple issued patents.
DM
David MackNamed on SEC filing
AL
Arnold LevineNamed on SEC filing
Board
PT
SW
Steve WinickBoard director
AO
Arnold OronskyBoard director
Investors · 6
Funding
SEC filings, press & company announcements$73.7M disclosed across 1 of 2 rounds · 2017–2020
- Undisclosed amountIPOSep 2020Source ↗
▶$73.7MraisedMar 2017 · 9 investors · PharmaceuticalsRule 506(b)
▶$73.7MraisedMar 2017 · 9 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- David MackExecutive Officer, Director
- Peter ThompsonDirector
- Steve WinickDirector
- Arnold OronskyDirector
- Arnold LevineDirector
- Offering amount
- $73.7M
- Amount sold
- $73.7M
- First sale
- Feb 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does PMV Pharma do?
- PMV Pharma develops precision oncology therapies that target and structurally correct mutated p53 proteins to restore their tumor-suppressing function. The company focuses on treating cancers driven by p53 mutations.
- Who founded PMV Pharma?
- PMV Pharma was founded by David H. Mack, Ph.D. in 2013.
- Who are PMV Pharma's investors?
- PMV Pharma's investors include Avoro Capital Advisors, Nextech Invest, OUP (Osage University Partners), RA Capital, OrbiMed, Osage University Partners.
- How much funding has PMV Pharma raised?
- PMV Pharma has disclosed $73.7M raised across 1 of its 2 known rounds.
- Where is PMV Pharma headquartered?
- PMV Pharma is headquartered in Cranbury, US.